Top-line data from a phase IIb/III study shows that Anave's (AVXL) lead drug exhibited statistical and clinical improvement in cognition and function in patients with early Alzheimer's disease.
Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?
Webcast and Conference Call To be Held Monday December 5, 2022, 8:30 am ETNEW YORK, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that management will host